Tags

Type your tag names separated by a space and hit enter

Multinuclear Organometallic Ruthenium-Arene Complexes for Cancer Therapy.
Met Ions Life Sci. 2018 02 05; 18MI

Abstract

There has been much recent interest in the development of therapeutic transition metal-based complexes in part fueled by the clinical success of the platinum(II) anticancer drug, cisplatin. Yet known platinum drugs are limited by their high toxicity, severe side-effects, and incidences of drug resistance. Organometallic ruthenium-arene complexes have risen to prominence as a pharmacophore due to the success of other ruthenium drug candidates in clinical trials. In this chapter, we highlight higher order multinuclear ruthenium-arene complexes and their respective investigations as chemotherapeutic agents. We discuss their unique structural properties and the associated biochemical evaluation in the context of anticancer drug design. We also review the structural considerations for the design of these scaffolds and new therapeutic applications that are uncovered for this class of complexes.

Authors

No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

29394025

Citation

Babak, Maria V., and Wee Han Ang. "Multinuclear Organometallic Ruthenium-Arene Complexes for Cancer Therapy." Metal Ions in Life Sciences, vol. 18, 2018.
Babak MV, Ang WH. Multinuclear Organometallic Ruthenium-Arene Complexes for Cancer Therapy. Met Ions Life Sci. 2018;18.
Babak, M. V., & Ang, W. H. (2018). Multinuclear Organometallic Ruthenium-Arene Complexes for Cancer Therapy. Metal Ions in Life Sciences, 18. https://doi.org/10.1515/9783110470734-012
Babak MV, Ang WH. Multinuclear Organometallic Ruthenium-Arene Complexes for Cancer Therapy. Met Ions Life Sci. 2018 02 5;18 PubMed PMID: 29394025.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Multinuclear Organometallic Ruthenium-Arene Complexes for Cancer Therapy. AU - Babak,Maria V, AU - Ang,Wee Han, PY - 2018/2/3/entrez PY - 2018/2/3/pubmed PY - 2018/7/3/medline JF - Metal ions in life sciences JO - Met Ions Life Sci VL - 18 N2 - There has been much recent interest in the development of therapeutic transition metal-based complexes in part fueled by the clinical success of the platinum(II) anticancer drug, cisplatin. Yet known platinum drugs are limited by their high toxicity, severe side-effects, and incidences of drug resistance. Organometallic ruthenium-arene complexes have risen to prominence as a pharmacophore due to the success of other ruthenium drug candidates in clinical trials. In this chapter, we highlight higher order multinuclear ruthenium-arene complexes and their respective investigations as chemotherapeutic agents. We discuss their unique structural properties and the associated biochemical evaluation in the context of anticancer drug design. We also review the structural considerations for the design of these scaffolds and new therapeutic applications that are uncovered for this class of complexes. SN - 1559-0836 UR - https://www.unboundmedicine.com/medline/citation/29394025/Multinuclear_Organometallic_Ruthenium_Arene_Complexes_for_Cancer_Therapy_ L2 - https://medlineplus.gov/cancerchemotherapy.html DB - PRIME DP - Unbound Medicine ER -